glp 1 and neuroinflammation GLP-1 programs the neurovascular landscape: Cell Metabolism Role of glucagon-like peptide-1 receptor

While GLP-1RAs demonstrate immunomodulatory potential relevant to SS pathogenesis through their effects on key immune cell populations, direct experimental evidence characterizing their impact on SS-specific immune dysregulation remains strikingly limited

without type 2 diabetes used glucagon-like peptide-1 (GLP-1) medication to help manage obesity

The answer is usually no. Notably, Epic Research data offers some reassurance on this front: two years after stopping a GLP-1, 56% of semaglutide patients, 52% of liraglutide patients and 55% of tirzepatide patients maintained at least some of their weight loss

Research suggests that using Semaglutide for at least 6 months to a year can result in significant, lasting weight loss

Semaglutide-related nausea is mild to moderate, follows a predictable 3-7 day peak after each dose, improves with meal adjustments and anti-nausea medications, and resolves within 8-12 weeks of treatment

Ongoing Support: A good provider doesn't just send you a vial and disappear